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De Novo Mutations in CHAMP1 Cause
Intellectual Disability with Severe Speech Impairment
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Johanna C. Herkert,5,10 Jonas Denecke,6 Tobias B. Haack,7,8 Alexander M. Zink,2 Jessica Becker,2
Eva Wohlleber,2 Jessika Johannsen,6 Bader Alhaddad,8 Rolph Pfundt,3 Sigrid Fuchs,1
Dagmar Wieczorek,9 Tim M. Strom,7,8 Koen L.I. van Gassen,4 Tjitske Kleefstra,3 Christian Kubisch,1
Hartmut Engels,2,11,* and Davor Lessel1,11,*
CHAMP1 encodes a protein with a function in kinetochore-microtubule attachment and in the regulation of chromosome segregation,
both of which are known to be important for neurodevelopment. By trio whole-exome sequencing, we have identified de novo delete-
rious mutations in CHAMP1 in five unrelated individuals affected by intellectual disability with severe speech impairment, motor devel-
opmental delay, muscular hypotonia, and similar dysmorphic features including short philtrum and a tented upper and everted lover lip.
In addition to two frameshift and one nonsense mutations, we found an identical nonsense mutation, c.1192C>T (p.Arg398*), in two
affected individuals. All mutations, if resulting in a stable protein, are predicted to lead to the loss of the functionally important zinc-
finger domains in the C terminus of the protein, which regulate CHAMP1 localization to chromosomes and themitotic spindle, thereby
providing a mechanistic understanding for their pathogenicity. We thus establish deleterious de novo mutations in CHAMP1 as a cause
of intellectual disability.Intellectual disability (ID) is defined as substantial impair-
ment of cognitive and adaptive functions with an onset in
childhood and has an estimated prevalence of 1.5%–
2.0%.1 The rapid development of new technologies,
including next-generation sequencing, has allowed for
the elucidation of a large number of previously undiag-
nosed Mendelian disorders during recent years. This holds
especially true for children with seemingly sporadic, non-
syndromic or mild dysmorphic forms of intellectual
disability and/or global developmental delay (ID/GDD)
who could not be analyzed systematically on a genome-
wide level before the advent of chromosomal microarrays
and whole-exome or genome sequencing. Indeed, recent
studies have identified pathogenic de novo mutations in
a rapidly growing number of individuals with ID/GDD
and thus have established the power of proband-parent
trio whole-exome sequencing in particular.2–4
Here, we report five unrelated individuals, three males
and two females, with ID/GDD, severe speech impairment,
and similar (though subtle) facial dysmorphisms (Table 1;
Figure 1). In all five individuals, trio whole-exome
sequencing identified causative de novo frameshift or
nonsense mutations in CHAMP1 (chromosome align-
ment-maintaining phosphoprotein 1; also called CAMP,
ZNF828, or C13orf8). CHAMP1 (GenBank: NM_032436.2;
MIM: 616327) encodes a zinc-finger protein, which is
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The Americanattachment during mitosis and the regulation of accurate
chromosome segregation,5 both known to be crucial for
cortical and mental development.6 All biological samples
and images were obtained after written informed consent
was given by the parents of the affected individuals. The
study was performed in accordance with the Declaration
of Helsinki protocols and approved by the ethics commit-
tees of the respective institutions.
The first proband (individual II-1 of family A) is the first
child of healthy unrelated parents of European descent. He
was born after an uneventful pregnancy at 40 weeks of
gestation with normal birth weight and length and a
borderline occipitofrontal head circumference (OFC) of
33 cm (2 SD). Feeding difficulties, vomiting, and weight
loss characterized the early postnatal period. Develop-
mental delay, muscular hypotonia, and strabismus first
became evident at the age of 3 months. Hyperopia was
diagnosed at the age of 9 months. All milestones of motor
development were delayed; he was rolling over at
12 months, sitting at 12 months, crawling at 30 months,
and walking at 4 years. At the age of four years, he dis-
played severe developmental delay with microcephaly
(OFC 2.2 SD) and truncal and orofacial hypotonia. His
gait was slightly ataxic, and he displayed stereotypic move-
ments including frequent hand fluttering and jactitation.
His behavior was very friendly and open-minded. In addi-
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Table 1. Clinical Characteristics of Individuals with De Novo CHAMP1 Mutations Presented Here
Individual A:II-1 Individual B:II-3 Individual C:II-2 Individual D:II-2 Individual E:II-2
Sex male male male female female
Birth at gestational week 40 39 39 37 40
Birth weight (g/SD) 3,520/0.4 3,580/þ0.2 3,100/0.9 3,105/þ0.3 4,100/þ1.5
Birth length (cm/SD) 52/0.2 ND 49/1.3 50/þ1.0 53/þ0.6
OFC at birth (cm/SD) 33/2.0 ND 35.6/2.1
(age 6 weeks)
29.5/3.1 35/0.4
(age 4 weeks)
Age at last examination (years) 4 3 18 3 8
Weight at last examination
(kg/SD)
16.3/þ0.2 14.7/0 50/2.7 14.7/0.1 45.5/þ3.3
Length at last examination
(cm/SD)
111.5/þ0.7 86/2.2 160/2.9 93.5/0.9 139/þ0.6
OFC at last examination
(cm/SD)
48/2.5 47.3/1.5 52.2/3.1 45.5/2.4 52/0.3
Neurological Signs
Muscular hypotonia þ þ þ þ þ
Motor development delay þ þ þ þ þ
Age of walking without support
(months)
48 36 30 18 20
Impaired speech development þ þ þ þ þ
Dysarthria, speech defect no speech no speech þ þ þ
Intellectual disability severe severe severe moderate moderate
Friendly behavior þ þ þ þ þ
Craniofacial Abnormalities
Orofacial hypotonia þ  þ þ þ
Long face þ  þ  þ
Epicanthic folds  þ  þ þ
Upslanting palpebral fissures  þ þ  þ
Short philtrum þ þ þ þ þ
Open-mouth appearance and
salivation
þ  þ þ þ
Thin and tented upper lip þ tented
(not thin)
þ þ þ
Everted lower lip þ þ þ þ þ
High arched palate þ þ ND þ þ
Pointed chin þ þ   þ
Low set ears  þ þ  þ
Other Findings
Strabismus þ  þ  
Hyperopia þ ND þ þ þ
Joint hypermobility þ  þ  
Neonatal feeding difficulties þ þ þ þ 
Umbilical hernia þ þ   
Decreased pain sensation þ  þ þ þ
Recurrent upper air tract infections  þ þ þ 
(Continued on next page)
494 The American Journal of Human Genetics 97, 493–500, September 3, 2015
Table 1. Continued
Individual A:II-1 Individual B:II-3 Individual C:II-2 Individual D:II-2 Individual E:II-2
Further Explorations
Cerebral MRI mild brain atrophy
and cerebellar cortical
dysplasia
slightly delayed
myelination
normal
(age one year)
normal
(age three months)
normal
(age three years)
CHAMP1Mutation
Gene mutation, protein alteration c.1866_1867delCA,
p.Asp622Glufs*8
c.1768C>T,
p.Gln590*
c.1192C>T,
p.Arg398*
c.635delC,
p.Pro212Leufs*7
c.1192C>T,
p.Arg398*
Abbreviations are as follows: þ, present; , absent; ND, not donedysmorphic features were observed, including a flattened
occiput, long face, short nose with anteverted nares, short
philtrum, thin and tented upper lip, everted lower lip,
pointed chin, high arched palate, and dysplastic teeth
(Figure 1A). Language development was significantly de-
layed and limited to three words at the age of 4 years. His
parents additionally observed decreased pain sensation. A
brain MRI, performed at the age of 4 years, revealed mild
generalized atrophy of the brain, a simplified gyral pattern,
and mild cerebellar cortical dysplasia resembling a mild
form of partial rhombencephalosynapsis with fused supe-
rior posterior cerebellar hemispheres but separated inferior
anterior cerebellar hemispheres (Figure S1). Conventional
chromosome analysis of lymphocytes, interphase fluores-
cence in situ hybridization (FISH) analysis in buccal swab
cells, array comparative genomic hybridization (CGH),
SNRPN-locus methylation analysis (MIM: 182279), and
direct sequencing of ARX (MIM: 300382) were performed,
all of which gave normal results. This prompted us to
perform trio exome sequencing with DNA samples of
both healthy parents and the proband, as described
before.2 In brief, coding DNA fragments were enriched
with a SureSelect Human All Exon 50Mb V5 Kit (Agilent),
and sequencing was performed on a HiSeq2500 system
(Illumina). Reads were aligned to the human genome
assembly hg19 (UCSC Genome Browser) with the Bur-
rows-Wheeler Aligner (BWA, v.0.5.87.5), and detection
of genetic variation was performed with SAMtools
(v.0.1.18), PINDEL (v. 0.2.4t), and ExomeDepth (v.1.0.0).
Bioinformatic filtering did not detect rare candidate vari-
ants (minor allele frequency [MAF] < 0.01) following an
autosomal-recessive or X-linked recessive mode of inheri-
tance. However, we identified a single non-annotated,
de novo sequence change with a severe impact on pro-
tein structure (Table S1A). This 2 bp deletion at cDNA
position 1,866 bp (c.1866_1867delCA) in CHAMP1 is
predicted to change the reading frame and to induce a pre-
mature stop codon at amino acid 629 (p.Asp622Glufs*8).
Sanger sequencing confirmed the heterozygous c.1866_
1867delCA mutation in the proband (Figure S2) and its
absence from blood DNA of both parents.
The second proband (individual II-3 of family B) is the
third child of non-consanguineous Dutch parents. The
boy was born after an unremarkable pregnancy at 39 weeksThe Americanof gestation. His birth weight was normal. In the neonatal
period, he had feeding difficulties and was tube-fed for six
weeks. A delayed development and impaired vision was
noted in the first month of his life. A brain MRI at the
age of 3 months showed slightly delayed myelination.
He was affected by severe hypotonia, which improved
over time. In addition, he suffered from recurrent upper
respiratory tract infections and aspiration pneumonias.
At the age of 2 years, an examination revealed several dys-
morphic features, including brachycephaly, a low frontal
hairline, hypertelorism, epicanthic folds, and a broad nasal
bridge. His height was at 2.2 SD, whereas his weight and
his OFC were within the normal range. He was able to
stand with some support at the age of 2.5 years and walk
a few steps without support but with insufficient head bal-
ance at the age of 3 years. He showed stereotypic behavior
characterized by turning, twisting movements of the arms
and hands, sighing, and shaking of his body. Nocturnal
frontotemporal epilepsy, probably causative for sleep
apnea, was successfully treated with carbamazepine. Even
though he has low vision with a suboptimal visual evoked
potential and normal electroretinogram, the cause of his
vision impairment is still unknown. At the age of 5 years,
a re-examination showed a very cheerful boy with stereo-
typies as described above, no speech and a frontal upsweep
of the hair, almond-shaped eyes, a high palate, small teeth,
and diasthema, in addition to the previously mentioned
dysmorphic features (Figure 1B). He had also developed
an umbilical hernia. Over time, basic metabolic studies,
sequence analysis of ATRX (MIM: 300032), SNP array,
and methylation studies for Prader-Willi syndrome
(MIM: 176270) yielded normal results. We therefore per-
formed trio-exome sequencing with DNA samples of the
parents and the proband, as described before.3 In brief,
exome-sequencing was performed with a SOLiD 5500XL
machine (Life Technologies) after enrichment with the
Agilent SureSelectXT Human All Exon 50Mb Kit (Agilent).
The data were analyzed with LifeScope software (Applied
Biosystems, Life Technologies). A de novo analysis was per-
formed with the parents and proband’s DNA, identifying a
single non-annotated, de novo sequence change with a
severe impact on protein structure (Table S1B). This was
single-nucleotide variant (SNV) c.1768C>T in CHAMP1,
resulting in a nonsense mutation at amino acid 590Journal of Human Genetics 97, 493–500, September 3, 2015 495
(p.Gln590*). Sanger sequencing confirmed the heterozy-
gous c.1768C>T mutation in the proband (Figure S3)
and its absence from blood DNA of both parents.
The third proband (individual II-2 of family C) is an
18-year-old male, the second of three children born to
non-consanguineous Dutch parents. He was born at gesta-
tional week 39 after an uneventful pregnancy and with a
normal birth weight and height. OFC at age 6 weeks
was 2.1 SD. Hypothermia and feeding problems charac-
terized the first days of life and esophageal reflux was
suspected. Hypotonia and developmental delay became
obvious in the first months. At the age of 1 year, develop-
mental delay and feeding problems associated with weight
loss led to an extensive clinical work up, revealing normal
results in metabolic analysis, MRI of the brain, determina-
tion of bone-age, skull X-ray, and pH-metry. Esophegaeal
motility analysis showed diminished swallowing move-
ments, but excluded a structural anomaly. Intermittent
exotropia and high hyperopia (þ6.25 diopters (dpt), bilat-
erally) were diagnosed. Clinical examination revealed
severe flattening of the occiput and increased spacing of
his large and prominent upper incisors. Feeding improved
over time. He suffered from repeated upper airway infec-
tions and gastritis. Motor milestones were delayed,
including rolling over at 9 months, sitting at 13 months,
and walking at 30 months. His language development
was also significantly delayed. He spoke first words at the
age of 3 years. Repeated elevation of pipecolic acid
in serum prompted an extensive metabolic workup,
including analysis in colony-stimulating factor, fibroblast,
and liver tissue. Normal results made a peroxisomal defect
unlikely. At the last visit at the age of 18 years, his
weight, length, and OFC were below the normal range
(weight 2.7 SD; height 2.9 SD; OFC 3.1 SD). Autism
had been diagnosed. He spoke in short sentences with
slurred speech. He loved music and swimming and was
able to operate his computer well. His behavior was
friendly. Parents reported a decreased pain sensation. Clin-
ical examination revealed muscular hypotonia, in partic-
ular orofacial hypotonia with open-mouth appearance
and salivation, a long face, upslanting palpebral fissures,
a short philtrum, a thin upper lip and everted lower lip, a
pointed chin, and low set ears (Figure 1C). Over the years,
karyotyping, array CGH, and FISH andmethylation testing
on chromosomal region 15q11q13, as well as analyses of
ARX, VPS13B (MIM: 607817), and UBE3A (MIM: 601623)
had been performed without pathogenic findings. This
prompted us to perform diagnostic trio exome sequencing
with DNA samples of the proband and both parents.
Exomes were enriched with the SureSelect XT Human All
Exon V5 Kit (Agilent) and sequenced in rapid run mode
on the HiSeq2500 sequencing system (Illumina). Reads
were aligned to hg19 with the BWA (BWA-MEM v.0.7.5a)
and variants were called with the Genome Analysis Toolkit
haplotype caller (v.2.7-2). Detected variants were anno-
tated, filtered, and prioritized with the Bench Lab NGS
platform (Cartagenia). De novo mutation analysis, by496 The American Journal of Human Genetics 97, 493–500, Septembfiltering all detected variants against parental and popula-
tion variants, identified a single non-annotated, de novo
sequence change with a severe impact on protein structure
(Table S1C). This was the CHAMP1 SNV c.1192C>T result-
ing in a nonsense mutation at amino acid 398 (p.Arg398*).
The heterozygous c.1192C>T mutation was validated and
proven to be de novo by Sanger sequencing (data not
shown).
The fourth proband (individual II-2 of family D) is a di-
chorionic diamniotic twin of Dutch origin. The mother
became pregnant after in vitro fertilization (IVF) by intra-
cytoplasmic sperm injection (ICSI) because of paternal
oligoasthenospermia. Pregnancy was complicated by pre-
eclampsia. The girl was born at 37 weeks and 2 days of
gestation and delivered by cesarean section. Her birth
weight and length were normal, but her OFC was below
the third centile. Directly after birth, a mild upslant of
the palpebral fissures, a short neck with a nuchal fold,
and swollen labia minora were noted. She was slightly hy-
potonic. Feeding difficulties and esophageal reflux were
present during the first weeks of life, and she was tube-
fed for 10 days. Aneuploidy for chromosomes X, Y, 13,
18, and 21 was excluded by quantitative fluorescent PCR
(qfPCR), and array CGH yielded normal results. Brain
MRI first showed reduced gyration and broad sulci,
although the diagnosis of simplified gyral pattern could
not be established. However, the brain MRI at 3 months
of age was reported to be normal. Magnetic resonance
spectroscopy showed no abnormalities of choline, crea-
tine, N-acetylaspartate (NAA), inositol, glutamate/gluta-
mine, or lactate. No cardiac or renal abnormalities were
noted. Her motor development was delayed. She started
walking at the age of 18 months. Bayley Scales of Infant
Development (BSID-III) testing at 2 years and 4 months re-
vealed a developmental delay of 12 months; her fine mo-
tor skills and speech development were delayed. Her recep-
tive language was better developed than her expressive
language. She suffered from recurrent upper respiratory
tract infections and a chronic otitis media. In addition,
high hyperopia (þ7 dpt) and astigmatism were diagnosed.
Her sleep was markedly disturbed, and there was no
improvement upon treatment with melatonin. A sleep
EEG showed no abnormalities, however the parents re-
ported staring spells during which she is not responsive.
Her behavior is very open and friendly and she has
a decreased pain sensation. She showed hand stereo-
typies, tactile hypersensitivity, and sexual self-stimulation.
Feeding difficulties were still present, especially in swal-
lowing certain solid foods. Clinical examination at age 3
years showedmild dysmorphic features, including full eye-
brows, epicanthic folds, a broad nasal bridge, slight lateral
eversion of lower eyelids, a short philtrum, orofacial hypo-
tonia with open mouth-appearance, a thin and tented
upper lip, a prominent lower lip, a high arched palate,
small teeth and diasthema (Figure 1D). Her gait was
clumsy and slightly broad-based. We performed trio
exome sequencing with DNA samples of the parents ander 3, 2015
Figure 1. Facial Phenotype of Individuals with
CHAMP1-Associated Disorder
Facial images of individual A:II-1 at age 4 years (A),
individual B:II-3 at the age of 12 months and
6 years (B), individual C:II-2 from the age of 6
till 18 years (C), individual D:II-2 at birth and at
age 3 years (D), and individual E:II-2 at the age 4
and 9 years (E). Note the long face, orofacial hypo-
tonia, epicanthic folds, upslanting palpebral fis-
sures, short philtrum, thin and tented upper lip
and everted lower lip, pointed chin, and deep-
set ears.the proband, as described above for individual II-3 of fam-
ily B, which identified a single non-annotated, de novo
sequence change (Table S1D). This 1 bp deletion atThe American Journal of HumacDNA position 635 (c.635delC) in CHAMP1
is predicted to change the reading frame
and to induce a premature stop codon at
amino acid 218 (p.Pro212Leufs*7). Sanger
sequencing confirmed the heterozygous
c.635delC mutation in the proband (data
not shown) and its absence from blood
DNA of both parents.
An independent deleterious de novo
CHAMP1 alteration has previously been
identified in a systematic trio exome-
sequencing study of 51 individuals with
severe non-syndromic ID.2 This CHAMP1
alteration is one of 87 de novo variants
in the proband group reported without
detailed clinical description in the supple-
mentary material. Due to the lack of further
affected individuals, the pathogenicity of
this variant remained unclear at that time.
Notably, this was the identical nonsense
mutation (c. 1192C>T; p.Arg398*; Figure S4)
that we also identified here in individual II-2
from family C. This fifth proband (individ-
ual II-2 of family E) is a nine-year-old girl,
the second child of healthy non-consan-
guineous German parents. Her mother
developed a Wilms tumor at the age of
24 years; further family history was unre-
markable. The probandwas born by vacuum
extraction after 40 weeks of gestation with
normal birth weight and length. OFC at
birth is unknown, though it was within
normal range at the age of four weeks. Psy-
chomotor developmental delay became
obvious in the second year of life. She
started crawling at the age of 11 months
and walking at the age of 20 months. Den-
ver scale testing at the age of 36 months re-
vealed a delay in all functions, particularly
in language development. Indeed, speech
development was markedly delayed, andshe just spoke tenwords at the age of 4 years and 8months.
Her receptive language skills were better in comparison,
but still delayed for her age. Basic metabolic studies,n Genetics 97, 493–500, September 3, 2015 497
EEGs, and a brain MRI at the age of 3 years yielded normal
results. Neurological examination at the age of 4 years
revealed orofacial hypotonia. The parents described a
decreased pain sensation. On examination at age 4 years
and 8 months, her body length and OFC were within
normal range, but she was overweight (BMI 19.8, þ3 SD).
She showed mild dysmorphic facial features including up-
slanting palpebral fissures, epicanthic folds, low-set ears, a
prominent nose, a short philtrum, an open-mouth appear-
ance with a thin and tented upper lip, a prominent lower
lip, and a high arched palate (Figure 1E). Her gait was
clumsy. Her behavior was very friendly and open-minded.
On last examination at 8 years and 11 months, her length
and OFC remained in the normal range, but obesity had
increased (BMI 23.3, þ3.3 SD). Her speech was slurred
and she spoke in up to three-word sentences and addition-
ally used hand signs. Orofacial hypotonia was still present.
The parents also reported truncal hypotonia. Meanwhile,
hyperopia (right, þ4.50 dpt; left, þ3.50 dpt) and bilateral
astigmatism were diagnosed. Prior to inclusion in the trio
exome-sequencing study, karyotyping, FISH testing on
chromosomal region 15q11q13 for Prader-Willi and Angel-
man (MIM: 105839) syndromes, fragile X analysis (MIM:
300624), MLPA P245 (microdeletion syndromes-1, MRC
Holland), and array-CGH analysis had given normal
results.
Taken together, all five individuals with a de novo dele-
terious CHAMP1 mutation are affected by ID and delayed
motor development with a particularly severe delay in
speech development. Whereas the motor development
improved over time, speech impairment remained. All
individuals suffered from muscular, in particular truncal,
hypotonia. Orofacial hypotonia was observed in four pro-
bands. Similar dysmorphic features, including a short
philtrum, tented upper lip, and everted lower lip were
observed in all individuals. Three individuals presented
with upslanting palpebral fissures, low-set ears, and a
long face and pointed chin. A friendly behavior was
described in all individuals. Decreased pain sensation,
feeding difficulties during the neonatal period, hyperopia,
and a high arched palate were noted in four individuals.
Three individuals displayed stereotypic movements. Three
individuals showed microcephaly. Before identifying the
causative CHAMP1 mutations, a number of different spe-
cific genetic tests had been performed. The most impor-
tant genetic differential diagnoses were Prader-Willi
(PWS) and Angelman syndromes (AS). PWS was suspected
in three probands because of feeding difficulties. At
toddler age, the severely delayed speech development,
the microcephaly, and ataxic gait made Angelman syn-
drome an important differential diagnosis, which was
tested in three probands. ARX analysis was performed
because of ID and speech delay in two male probands.
Notably, none of the four CHAMP1 alterations identified
in our study were present in dbSNP136, the ExAC database,
or the 1000 Genomes data, indicating that they are very
rare in the population and unlikely to be disease-unrelated498 The American Journal of Human Genetics 97, 493–500, Septembalterations. Additional confirming evidence of the patho-
genic nature of CHAMP1mutations in our probands comes
from a very recent large-scale sequencing study (Decipher-
ing Developmental Disorders) in altogether 1,133 individ-
uals with ID and developmental delay. In this study, dele-
terious de novo CHAMP1 alterations were reported in
two independent individuals. The first proband was a
boy bearing the SNV c.1002G>A predicted to result in
the nonsense variant at amino acid 334 (p.Trp334*) and
who was reported to show ID, obstructive sleep apnea, su-
pernumerary nipples, and plagiocephaly. The second pro-
band was a girl bearing the SNV c.1489C>T, resulting in
a nonsense variant at amino acid 497 (p.Arg497*) and
who showed GDD, joint hypermobility, abnormalities of
the renal collecting system and the CNS, incoordination,
and diastasis recti. The authors classified CHAMP1 as a
‘‘novel gene with compelling evidence for a role in devel-
opmental disorders.’’4
The findings in altogether seven independent individ-
uals thus confirm that mutations in CHAMP1 are a mono-
genic cause of ID/GDD. In line with this assumption, there
is no single loss-of-function CHAMP1 variant deposited
in the ExAC database, including more than 110,000
sequenced alleles at this locus, which argues strongly
for a deleterious effect of CHAMP1 mutations. Notably,
the Residual Variation Intolerance (RVI) score, which
quantifies gene intolerance to functional mutations7 of
CHAMP1, is 0.75 (13.71th percentile) and thus even
lower than the average RVI score for genes involved in
developmental disorders (0.56; 19.54th percentile). This
suggests that the degree of intolerance to deleterious vari-
ants of CHAMP1 is significantly more pronounced than
the average degree of intolerance to deleterious variants
of genes known to have mutations that cause develop-
mental disorders.
CHAMP1 is located at chromosome 13q34 and contains
a single coding exon (as well as two 50-untranslated exons)
encoding for a zinc-finger protein of 812 amino acids.
CHAMP1 was shown to interact with the mitotic control
protein MAD2L2 and is required for its spindle localiza-
tion. CHAMP1 localizes to chromosomes and the mitotic
spindle and regulates localization of CENPE and CENPF
to kinetochores. Furthermore, it regulates kinetochore-
microtubule attachment and therefore proper chromo-
some alignment.5 Mutations affecting genes encoding for
proteins that regulate chromosome alignment and/or
spindle assembly are a well-established cause of a variety
of syndromic and non-syndromic developmental disor-
ders. Examples include POGZ (MIM: 614787),4 KIF2A
(MIM: 602591), TUBG1 (MIM: 191135),6 KIF4A (MIM:
300521) and KIF5C (MIM: 604593),8 CENPE (MIM:
117143),9 and BUB1B (MIM: 602860).10 Therefore,
CHAMP1 represents an attractive functional candidate
gene for a developmental disorder. Interestingly, it
has been shown that the localization of CHAMP1 to chro-
mosomes and the mitotic spindle is regulated by its C-ter-
minal region containing zinc-finger domains. The latterer 3, 2015
Figure 2. Schematic Protein Structure of CHAMP1
The positions of the de novo mutations identified in this study are marked with vertical arrows and are shown in red; mutations iden-
tified in the Deciphering Developmental Disorders study are shown in black. Abbreviations are as follows: ZnF, zinc-finger domain; N, N
terminus; C, C terminus.were further shown to be required for proper chromosome
alignment.5 Notably, all thus-far-identified deleterious de
novo mutations, if resulting in a stable protein, are pre-
dicted to lead to the loss of this functionally important
C-terminal domain (Figure 2).
Notably, several chromosomal deletions involving
CHAMP1 have been reported. Microscopically visible dele-
tions of chromosome 13q have been divided into three
groups depending on the localization of the deleted re-
gions. Individuals of group 3, i.e., those with deletion
breakpoints distal to 13q32, have been reported to be
characterized by moderate to severe ID and, in the major-
ity of cases, the absence of major malformations and
growth deficiencies.11 More recent reports on individuals
with deletions of 13q33–13q34 have expanded this clin-
ical spectrum. For example, one individual was reported
to have a cleft palate, microcephaly, and hypospadia in
addition to his moderate to severe ID with severe speech
delay.12 Another individual with intrauterine growth
retardation, generalized hypotonia, severe language delay,
and facial dysmorphism including epicanthal folds is re-
ported to be socially outgoing, similar to the SNV-bearing
individuals reported here.13 Clinical similarities with the
individuals reported here also exist in individuals with
submicroscopic deletions including CHAMP1 reported in
the DECIPHER database or previous publications. 23 out
of 26 individuals bearing a deletion that affects chromo-
somal bands 13q33 and 13q34 only (maximum size
13.5 Mb, Table S2) are reported to display ID/GDD. One
may thus hypothesize that deletion of CHAMP1 may be
the main cause for ID/GDD in individuals with deletion
CNVs of terminal 13q. Interestingly, several other
frequent findings in the five individuals reported here
are also present in several individuals with deletions of
13q33–13q34, such as muscular hypotonia (n ¼ 5), a nar-
row or high arched palate (n ¼ 5), speech delay or an
arched upper lip (each n ¼ 3), as well as upslanting palpe-
bral fissures or epicanthic folds (each n ¼ 3). Given the
incompleteness of database entries, this should of course
not be over-interpreted. However, some of the published
probands display three to four of these additional fea-
tures.14 Thus, CHAMP1 may at least partly be responsible
for some of the clinical features besides ID in individuals
with group 3 chromosome 13q deletions. Given that the
clinical findings of individuals with de novo mutations
in CHAMP1 and in probands with larger chromosomal de-The Americanletions encompassing the complete CHAMP1 gene seem
comparable, it is tempting to speculate that this may be
an indication for haploinsufficiency as the common etio-
logical mechanism.
In summary, we identified five ID-affected individuals
bearing de novo deleterious mutations in CHAMP1. Our
data therefore establish deleterious mutations in CHAMP1
as themonogenic cause of a developmental disorder. More-
over, we provide the first detailed clinical description of
individuals with CHAMP1 mutations, revealing ID with
severely impaired expressive speech and delayed motor
development, muscular hypotonia, neonatal feeding diffi-
culties, and hyperopia, as well as similar mild dysmorphic
features, as common clinical signs. In addition, we suggest
that the genetic analysis of CHAMP1 should be considered
in individuals with unclassified, non-syndromic or mild
dysmorphic forms of ID/GDD, especially if muscular hypo-
tonia and severe speech delay are present and PWS and AS
testing have given normal results. Finally, our data further
highlight the importance of the kinetochores and chromo-
somal alignment for proper human neuronal development
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